Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals
- 3 June 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (9) , 2460-2467
Abstract
Objectives: There are limited data regarding efavirenz pharmacogenetics in admixed populations. The Brazilian population is highly admixed. In a Brazilian cohort, we sought to characterize associations between efavirenz adverse effects (all-cause and CNS) and polymorphisms in seven genes known or suspected to affect efavirenz metabolism and transport. Methods: We studied 225 HIV-positive individuals who had been prescribed efavirenz-containing regimens at a hospital in Rio de Janeiro, Brazil. Eighty-nine cases had efavirenz adverse effects, including 43 with CNS adverse effects, while 136 controls had no adverse effect of any antiretroviral after treatment for at least 6 months. A total of 67 candidate polymorphisms in ABCB1, CYP2A6, CYP2B6, CYP3A4, CYP3A5, NR1I2 and NR1I3 genes were selected for association analysis. Admixture was assessed using 28 ancestry-informative polymorphisms previously validated for the Brazilian population. Associations were evaluated with logistic regression models adjusted for sex and genetic ancestry. Results: There was extensive African, European and Native American admixture in the cohort. Increased all-cause adverse effects were associated with the CYP2B6 genotype combination 15582CC-516TT-983TT (OR=7.26, P=0.003) and with the CYP2B6 slow metabolizer group 516TT or 516GT-983CT (OR=3.10, P=0.04). CNS adverse effects were nominally associated with CYP3A4 rs4646437 (OR=4.63, P=0.014), but not after adjusting for multiple comparisons. Conclusions: In a highly admixed Brazilian cohort, the CYP2B6 slow metabolizer genotype was associated with an increased risk of efavirenz adverse effects.Keywords
Funding Information
- Brazilian Ministry of Health (TC 235/2012)
- National Institutes of Health (AI077505, AI069439, TR002243)
This publication has 46 references indexed in Scilit:
- Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort studyBMC Infectious Diseases, 2013
- PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patientsBMC Medical Genetics, 2012
- Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group StudyThe Journal of Infectious Diseases, 2010
- Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-HydroxylationDrug Metabolism and Disposition, 2010
- Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsAIDS Research and Therapy, 2010
- CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsAIDS, 2009
- Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with ZidovudineDrug Metabolism and Disposition, 2009
- Inferring weak population structure with the assistance of sample group informationMolecular Ecology Resources, 2009
- Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2008
- Inference of population structure using multilocus genotype data: dominant markers and null allelesMolecular Ecology Notes, 2007